DMD Drugs Take Center-stage As Sarepta Waits On Accelerated Approval Go/No-Go
This article was originally published in The Pink Sheet Daily
Executive Summary
New data from GSK and Prosensa has Sarepta investors eager for news on the future of its drug as competition heats up in the rare disease space.